Multivariate analysis of variables affecting PFS from start of consolidation therapy
| Variable . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| β2-microglobulin < 3.5 mg/L | 0.42 | 0.29-0.61 | < .0001 |
| Absence of t(4;14) and del(17p) | 0.49 | 0.34-0.73 | < .0001 |
| Consolidation with VTD | 0.61 | 0.42-0.89 | .010 |
| Variable . | Hazard ratio . | 95% CI . | P . |
|---|---|---|---|
| β2-microglobulin < 3.5 mg/L | 0.42 | 0.29-0.61 | < .0001 |
| Absence of t(4;14) and del(17p) | 0.49 | 0.34-0.73 | < .0001 |
| Consolidation with VTD | 0.61 | 0.42-0.89 | .010 |
VTD indicates bortezomib with thalidomide plus dexamethasone.